U.S. markets close in 2 hours 54 minutes

WeedMD Inc. (WDDMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2344+0.0014 (+0.61%)
As of 12:07PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2330
Open0.2700
BidN/A x N/A
AskN/A x N/A
Day's Range0.2344 - 0.2700
52 Week Range0.1680 - 0.8200
Volume94,638
Avg. Volume97,069
Market Cap52.045M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • WeedMD Expands Starseed Medicinal Access to Atlantic Canada Alongside Leading Cannabis Physician and Advocate Dr. Julie Hildebrand
    GlobeNewswire

    WeedMD Expands Starseed Medicinal Access to Atlantic Canada Alongside Leading Cannabis Physician and Advocate Dr. Julie Hildebrand

    New Brunswick-based physician leads Company’s clinical expansion into the Atlantic region WeedMD Expands Starseed Medicinal Access to Atlantic Canada Alongside Leading Cannabis Physician and Advocate Dr. Julie Hildebrand New Brunswick-based physician, Dr. Hildebrand specializes in cannabis medicine, chronic pain, diabetes and opioid-cessation treatments. She leads the Company's clinical expansion into the Atlantic Region.TORONTO, Nov. 26, 2020 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally licensed producer and distributor of medical-grade cannabis, is pleased to announce it has expanded its North Star Wellness Virtual Patient Care Program and access to its Starseed Medicinal products to Atlantic Canada under the purview of New Brunswick-based physician, Dr. Julie Hildebrand.Dr. Hildebrand, widely recognized in the region for specializing in cannabis medicine and education, will work with patients and benefits providers in New Brunswick, Nova Scotia, Prince Edward Island and Newfoundland. Dr. Hildebrand will connect with patients in one of the country’s fastest-growing medical cannabis markets, leveraging her extensive clinical expertise in chronic pain and diabetes.“Expanding our coverage area to Atlantic Canada alongside a leading cannabis medicine advocate such as Dr. Hildebrand, will introduce more patients to Starseed’s unique medical platform and portfolio of treatment options,” said Angelo Tsebelis, CEO of WeedMD. “Together with our North Star Wellness Virtual Patient Care Program, we will continue providing consultations to new and existing patients through an advanced, accessible healthcare platform. With medical cannabis therapies and product advancements on the rise, we applaud Dr. Hildebrand as a strong cannabis proponent.”Echoing the necessity for solutions that improve upon traditional access, Dr. Peter Blecher, Chief Medical Officer of WeedMD and North Star Wellness Clinics added: “The Atlantic region’s healthcare system is overburdened with opioid addiction and the need for alternate therapies. Dr. Hildebrand will provide extended assessments to patients seeking standardized treatment and dosing options, as well as a platform to assist patients if their primary care providers are unavailable.”Dr. Hildebrand is a physician with more than 30 years of biomedical research and medical experience. She is widely published in over 40 communications, papers and publications on cannabis medicine as a new therapy, effects of opioid addiction, methadone treatment analysis, mental health and addiction. A fluently-bilingual researcher and professor, she is the medical director of the Methadone Maintenance Therapy Program at Saint Joseph’s Hospital in Saint John, NB. Dr. Hildebrand holds a B.Sc. in Biology (specialty in Physiology-Toxicology) and an MBA from the Université du Québec à Montréal (UQAM), and is a PhD candidate in Management and Technology from UQAM, McGill University and Concordia University. She obtained her Doctorate in Medicine from the Université Laval along with a specialty in Family Medicine. She also holds a Medical Licence in Opioid Dependence Treatment Certificate – CAMH – University of Toronto.“Physicians have a responsibility to carefully assess and educate patients on treatment options that may be most effective to improve their health and quality of life. It’s our duty to become well-informed and counsel patients on all available medicines and treatments that can provide the highest level of care,” said Dr. Hildebrand. “The Starseed platform is designed to enable physicians to provide that high-bar support with cannabis, particularly as an exit treatment for chronic opioid use. I’m proud to collaborate with WeedMD on this important work in my home region in Atlantic Canada.”Starseed Unique Pharmacy Model and the North Star Wellness ProgramStarseed’s medical marketplace is a revolutionary Canadian system built around a virtual pharmacy system that takes online orders and intuitively completes the claims management process seamlessly with insurance carriers. The North Star Wellness platform connects healthcare professionals with patients and provides medical management, education and streamlined access to clinical services. All WeedMD and Starseed medical patients have free access to North Star’s full suite of services. Since its launch in 2017, the platform has continued to expand and now offers its Virtual Patient Care Program as the sector transitions into virtual healthcare. North Star Wellness is a wholly owned affiliate of WeedMD.    Information about upcoming corporate events can be found here. Access WeedMD’s latest investor deck here. About WeedMD Inc.WeedMD Inc. is the publicly-traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario as well as a fully-licensed 26,000 sq. ft. Aylmer, Ontario processing facility, specializing in cannabis extraction. With the addition of Starseed, a medical-centric operator based in Bowmanville, Ontario, WeedMD has expanded its multi-channeled distribution strategy. Starseed’s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with other employers and union groups complements WeedMD’s direct sales to medical patients. The Company maintains strategic relationships in the seniors’ market and supply agreements with Shoppers Drug Mart as well as seven provincial distribution agencies where adult-use brands Color Cannabis and Saturday are sold.Follow WeedMD, Color Cannabis & Starseed: LinkedIn: https://ca.linkedin.com/company/weedmd Twitter: https://twitter.com/WeedMD Instagram: https://www.instagram.com/weedmd/ Instagram: https://www.instagram.com/callitcolor/ & Instagram: https://www.instagram.com/starseedca/       For further information, please contact:For Investor Enquiries: Valter Pinto Managing Director KCSA Strategic Communications 1-212-896-1254 weedmd@kcsa.comFor Media Enquiries:                                 Victoria Dekker Communications & Corporate Affairs 1-506-962-6565 victoria.dekker@weedmd.comForward Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon WeedMD's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; the COVID-19 pandemic; competition; crop failure; and other risks.Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASEA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2d1975c3-ebc1-4c61-8237-4c1fa237deda

  • WeedMD Schedules Third Quarter 2020 Conference Call for December 1st, 2020
    GlobeNewswire

    WeedMD Schedules Third Quarter 2020 Conference Call for December 1st, 2020

    Company financials and operational outlook to be filed after market on November 30, 2020TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis, announced today that it will file its financial statements and management’s discussion and analysis for the third quarter ended September 30, 2020, after market close on Monday, November 30, 2020. The Company will host a conference call to discuss these results, recent corporate developments and provide an operational update, on Tuesday, December 1st, 2020 at 10 a.m. Eastern Time. The call will be hosted by CEO Angelo Tsebelis and CFO Lincoln Greenidge. Management will be available for questions following opening remarks.Conference Call Details: Date:Tuesday, December 1st, 2020 Time:10 a.m. Eastern Time Dial-in Number:Canada/USA: 1-800-319-4610. International Toll: 1-604-638-5340 Participants, please dial in and ask to join the WeedMD call Replay Dial-in:Canada/USA: 1-800-319-6413. International Toll: 1-604-638-9010 Replay Access Code: 5599 Available after 12:00 p.m. Eastern Time, until January 1, 2021 Information about upcoming corporate events can be found here. Access WeedMD’s latest investor deck here. About WeedMD Inc.WeedMD Inc. is the publicly-traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario as well as a fully-licensed 26,000 sq. ft. Aylmer, Ontario processing facility, specializing in cannabis extraction. With the addition of Starseed, a medical-centric operator based in Bowmanville, Ontario, WeedMD has expanded its multi-channeled distribution strategy. Starseed’s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with other employers and union groups complements WeedMD’s direct sales to medical patients. The Company maintains strategic relationships in the seniors’ market and supply agreements with Shoppers Drug Mart as well as six provincial distribution agencies where adult-use brands Color Cannabis and Saturday are sold.Follow WeedMD, Color Cannabis & Starseed:LinkedIn: https://ca.linkedin.com/company/weedmd Twitter: https://twitter.com/WeedMD Instagram: https://www.instagram.com/weedmd/ Instagram: https://www.instagram.com/callitcolor/ & Instagram: https://www.instagram.com/starseedca/ For further information, please contact:For Investor Enquiries: Valter Pinto Managing Director KCSA Strategic Communications 1-212-896-1254 weedmd@kcsa.comFor Media Enquiries: Marianella delaBarrera VP, Communications & Corporate Affairs 416-897-6644 marianella@weedmd.comForward Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon WeedMD's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; the COVID-19 pandemic; competition; crop failure; and other risks.Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE

  • WeedMD’s Color Cannabis Vaporizers Make Strong Entry in Ontario
    GlobeNewswire

    WeedMD’s Color Cannabis Vaporizers Make Strong Entry in Ontario

    Color Cannabis Vaporizers Make Strong Entry in Ontario WeedMD kicks off vape launch with Color Cannabis, in strain-specific Pedro's Sweet Sativa and Ghost Train Haze - now available in Ontario and expanding soon to other retailers and provinces.First week of shipment to Ontario Cannabis Store (OCS) sends strain-specific Color Cannabis 510 vapes to “OCS Top 5” status as availability expands to retailers and other provinces TORONTO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WeedMD Inc. (TSX-V:WMD) (OTCQX:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical-grade cannabis is pleased to announce it has commenced shipping its Color Cannabis-branded 510 vaporizer cartridges (“vapes”) to Canada’s largest retail distributor, the Ontario Cannabis Store (“OCS”). Color vapes landed in the “Top 5” status when compared to over 30 available vape brands during its first week of availability, according to OCS-provided data.WeedMD’s legacy cultivars Pedro Sweet Sativa and Ghost Train Haze, are produced at the Company’s state-of-the-art extraction hub utilizing WeedMD’s own terpene-rich biomass. Additional strain-specific offerings, such as Mango Haze and Black Sugar Rose, are scheduled to follow soon.“The initial success of our Color vapes in Canada’s largest retail market is a significant milestone for our team and reflects the increased brand recognition and strong consumer interest in our quality-derived products,” said Stephen Ng, Chief Commercial Officer. “Our terpene-rich products under Color and Saturday are garnering national appeal as we prepare to launch a broader portfolio of products from our best-in-class cultivation and production platform.”In addition to Color vapes, WeedMD recently launched a new cultivar ‘Black Sugar Rose’ coming this fall, as well as strain-specific pre-roll products, nitrogen-infused packaging and a brand partnership with PAX Labs Inc. for its PAX® ERA® and ERA PRO™line of strain-specific vapes. The Company also announced it is the exclusive Canadian supplier and distributor of acclaimed U.S.-based wellness house Mary’s Medicinals, with topicals production slated to commence at WeedMD’s extraction hub in Aylmer, ON later this year.    Information about upcoming corporate events can be found here. Access WeedMD’s latest investor deck here. About WeedMD Inc.WeedMD Inc. is the publicly-traded parent company of WeedMD RX Inc. and Starseed Medicinal Inc., licence holders producing and distributing cannabis products for both the medical and adult-use markets. The Company owns and operates a 158-acre state-of-the-art greenhouse, outdoor and processing facility located in Strathroy, Ontario as well as a fully-licensed 26,000 sq. ft. Aylmer, Ontario processing facility, specializing in cannabis extraction. With the addition of Starseed, a medical-centric operator based in Bowmanville, Ontario, WeedMD has expanded its multi-channeled distribution strategy. Starseed’s industry-first, exclusive partnership with LiUNA, the largest construction union in Canada, along with other employers and union groups complements WeedMD’s direct sales to medical patients. The Company maintains strategic relationships in the seniors’ market and supply agreements with Shoppers Drug Mart as well as seven provincial distribution agencies where adult-use brands Color Cannabis and Saturday are sold.Follow WeedMD, Color Cannabis & Starseed: LinkedIn: https://ca.linkedin.com/company/weedmd Twitter: https://twitter.com/WeedMD Instagram: https://www.instagram.com/weedmd/ Instagram: https://www.instagram.com/callitcolor/ & Instagram: https://www.instagram.com/starseedca/For further information, please contact:For Investor Enquiries: Valter Pinto Managing Director KCSA Strategic Communications 1-212-896-1254 weedmd@kcsa.comFor Media Enquiries: Marianella delaBarrera VP, Communications & Corporate Affairs 416-897-6644 marianella@weedmd.comForward Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon WeedMD's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; the COVID-19 pandemic; competition; crop failure; and other risks.Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASEA photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/58dd036b-2317-41bf-897a-eba64e5575b9